Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10616188 | 0.89 | CYP3A4 (0.50) | CYP3A4ADORA2BADORA2ACYP1A2CYP2D6 | |
| SCHEMBL3981817 | 0.84 | ADORA2B (0.46) | CYP3A4ADORA2BADORA2ACYP1A2CYP2D6 | |
| SCHEMBL3979483 | 0.82 | ADORA2B (0.45) | CYP3A4ADORA2BADORA2ACYP1A2CYP2D6 | |
| SCHEMBL4186443 | 0.80 | SMN1; SMN2 (0.43) | CYP3A4ADORA2ACYP1A2CYP2D6KMT2A | |
| SCHEMBL6571379 | 0.78 | CYP3A4 (0.50) | CYP3A4ADORA2BADORA2ACYP1A2CYP2D6 | |
| SCHEMBL28662 | 0.75 | CYP3A4 (1.00) | CYP3A4ADORA2BADORA2ACYP1A2CYP2D6 | |
| SCHEMBL5449552 | 0.74 | CYP3A4 (0.50) | CYP3A4ADORA2BADORA2ACYP1A2CYP2D6 | |
| SCHEMBL475981 | 0.74 | CYP3A4 (0.46) | CYP3A4ADORA2BADORA2ACYP1A2CYP2D6 | |
| SCHEMBL21592085 | 0.70 | CYP3A4 (0.76) | CYP3A4ADORA2BADORA2ACYP1A2CYP2D6 | |
| SCHEMBL2778902 | 0.70 | CYP3A4 (0.44) | CYP3A4ADORA2BADORA2ACYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111072574-A | 5, 6-diamino-1, 3-dialkyl substituted uracil and its preparation method | 广东工业大学 | 2020-04-28 | — | — | CN | claimed |
| US-20060211045-A1 | Fluorescently tagged ligands | CELLAURA TECHNOLOGIES LIMITED (GB) | 2006-09-21 | — | — | US | claimed |
| JP-11080128-A | — | — | None | — | — | JP | disclosed |
| JP-11080128-A | — | — | None | — | — | JP | disclosed |
| CN-102532137-B | 8-pyrazole substituted xanthine A2B adenosine receptor antagonist and synthesis method and application thereof | UNIV LIAONING MEDICAL | 2014-12-10 | — | — | CN | disclosed |
| CN-102532137-A | 8-pyrazole substituted xanthine A2B adenosine receptor antagonist and synthesis method and application thereof | UNIV LIAONING MEDICAL | 2012-07-04 | — | — | CN | disclosed |
| US-7335655-B2 | 8-heteroaryl xanthine adenosine A2B receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7205403-B2 | 8-Heteroaryl xanthine adenosine A2B receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| US-20060211045-A1 | Fluorescently tagged ligands | CELLAURA TECHNOLOGIES LIMITED (GB) | 2006-09-21 | — | — | US | disclosed |
| US-20060142309-A1 | 8-Heteroaryl xanthine adenosine A2B receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2006-06-29 | — | — | US | disclosed |
| EP-1623223-A2 | FLUORESCENTLY TAGGED LIGANDS | THE UNIVERSITY OF NOTTINGHAM (GB) | 2006-02-08 | — | — | EP | disclosed |
| EP-0449175-A2 | Selective adenosine receptor agents | MERRELL PHARMACEUTICALS INC. (US) | 1991-10-02 | — | — | EP | disclosed |
| US-5047534-A | Xanthine derivatives; hyupotensive agents, cardiotonic agents | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-09-10 | — | — | US | disclosed |
| WO-1990012797-A1 | SULFER-CONTAINING XANTHINE DERIVATIVES AS ADENOSIN ANTAGONISTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) | 1990-11-01 | — | — | WO | disclosed |
| US-4783530-A | CARDIOTONIC AND BRONCHODILATOR AGENTS | MARION LABORATORIES, INC. (US) | 1988-11-08 | — | — | US | disclosed |
| US-4769377-A | Adenosine receptor antagonists | THE JOHNS HOPKINS UNIVERSITY (US) | 1988-09-06 | — | — | US | disclosed |
| EP-0267607-A1 | 8-Arylxanthines | MARION MERRELL DOW INC. (US) | 1988-05-18 | — | — | EP | disclosed |
| US-4593095-A | ADENOSINE RECEPTOR ANTAGONISTS | THE JOHNS HOPKINS UNIVERSITY (US) | 1986-06-03 | — | — | US | disclosed |
| US-4120947-A | Xanthine compounds and method of treating bronchospastic and allergic diseases | COOPER LABORATORIES, INC. (US) | 1978-10-17 | — | — | US | disclosed |
| US-4089959-A | Long-acting xanthine bronchodilators and antiallergy agents | COOPER LABORATORIES, INC. (US) | 1978-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142309-A1 | 8-Heteroaryl xanthine adenosine A2B receptor antagonists | ADORA2B, ADORA2A, ADORA1 | CYP3A4 1314/4885ADORA2B 1/4885ADORA2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.